| |
Patients (%)
|
mPFS months (95% CI)
|
P-value
|
|---|
|
Age
|
|
<60
|
203 (50.5)
|
4.3 (3.8-4.7)
|
0.840
|
|
≥ 60
|
199 (49.5)
|
4.5 (3.9-5.1)
| |
|
Gender
|
|
Male
|
293 (72.9)
|
4.5 (3.9-5.0)
|
0.381
|
|
Female
|
109 (27.1)
|
4.3 (3.6-4.9)
| |
|
Liver Mets
|
|
Yes
|
125 (31.1)
|
4.1 (3.6-4.5)
|
0.243
|
|
No
|
277 (68.9)
|
4.6 (3.9-5.2)
| |
|
Peritoneal Mets
|
|
Yes
|
159 (39.6)
|
4.3 (3.8-4.8)
|
0.128
|
|
No
|
243 (60.4)
|
4.6 (3.9-5.2)
| |
|
Bone Mets
|
|
Yes
|
28 (7.0)
|
3.9 (2.4-5.3)
|
0.032
|
|
No
|
374 (93.0)
|
4.5 (4.0-5.0)
| |
|
Albumin
|
|
<3.5
|
77 (19.2)
|
3.4 (2.2-4.5)
|
0.013
|
|
≥ 3.5
|
325 (80.8)
|
4.6 (4.1-5.2)
| |
|
CRP
|
|
≤ 1
|
262 (65.1)
|
5.3 (4.5-6.0)
|
0.001
|
|
>1
|
140 (34.9)
|
3.4 (2.7-4.1)
| |
|
ECOG PS
|
|
0-1
|
329 (81.8)
|
4.6 (4.0-5.1)
|
0.002
|
|
≥ 2
|
73 (48.2)
|
3.0 (2.0-3.9)
| |
|
GPS
|
|
0
|
238 (59.2)
|
5.5 (4.8-6.2)
|
0.001
|
|
1
|
111 (27.6)
|
3.4 (2.7-4.1)
| |
|
2
|
53 (13.2)
|
3.3 (2.0-4.7)
| |
- mPFS: median progression free survival, Mets: Metastasis, CRP: C-reactive protein, ECOG PS: Eastern Cooperative Oncology Group, performance status, GPS: Glascow prognostic score
